Jennifer Sampang
Psychiatric/Mental Health · Crestview Hills, KYNPI 1396745899
Payments from drug & device makers
Across 855 payments — averaging $376.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$137K
- Acadia Pharmaceuticals Inc$75K
- AbbVie$58K
- Axsome Therapeutics, Inc.$24K
- Avanir Pharmaceuticals, Inc.$16K
- Otsuka America Pharmaceutical, Inc.$8K
- plus $5K from 16 others
What the payments were for
- Consulting fees$25,6818%
- Speaking & faculty fees$247,61577%
- Travel & lodging$28,3739%
- Food & beverage$20,3876%
- Education$2550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 267 | $136,783 |
| Acadia Pharmaceuticals Inc | 170 | $74,619 |
| AbbVie(2 entities) | 223 | $58,401 |
| Axsome Therapeutics, Inc. | 38 | $23,734 |
| Avanir Pharmaceuticals, Inc. | 37 | $15,814 |
| Otsuka America Pharmaceutical, Inc. | 52 | $7,612 |
| Idorsia Pharmaceuticals US Inc | 9 | $4,178 |
| Johnson & Johnson | 9 | $245 |
| Lundbeck LLC | 12 | $231 |
| Sunovion Pharmaceuticals Inc. | 7 | $116 |
| Alkermes, Inc. | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $90 |
| Neurocrine Biosciences, Inc. | 4 | $74 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $67 |
| Eisai Inc. | 3 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $52 |
| Alpha Cognition USA, Inc. | 2 | $50 |
| Noven Therapeutics, LLC | 2 | $27 |
| Almatica Pharma LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Bioxcel Therapeutics, Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$72,071
- Austedo XR$64,496
- AUSTEDO$59,261
- VRAYLAR$54,812
- Auvelity$22,923
- NUEDEXTA$19,034
- UZEDY$8,252
- QUVIVIQ$4,009
- REXULTI$2,923
- ABILIFY MAINTENA$217
- ABILIFY ASIMTUFII$116
- SPRAVATO$106
How this compares
$322,312 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 141 | $1,390,927 |
| NuplazidPimavanserin Tartrate | 34 | $175,888 |
| VraylarCariprazine Hcl | 74 | $106,812 |
| IngrezzaValbenazine Tosylate | 12 | $99,271 |
| NuedextaDextromethorphan Hbr/Quinidine | 47 | $73,081 |
| RexultiBrexpiprazole | 80 | $72,625 |
| TrintellixVortioxetine Hydrobromide | 21 | $18,621 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,321 |
| ExelonRivastigmine | 15 | $9,231 |
| Rivastigmine | 31 | $6,846 |
| Duloxetine Hcl | 195 | $6,051 |
| Vilazodone Hcl | 57 | $6,004 |
| Divalproex Sodium ErDivalproex Sodium | 56 | $5,094 |
| Buspirone Hcl | 234 | $4,937 |
| Mirtazapine | 91 | $4,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $136,783 | $1,390,927141 claims |
| Acadia Pharmaceuticals IncNuplazid | $74,619 | $175,88834 claims |
| AbbVieVraylar | $58,401 | $106,81274 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $74 | $99,27112 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $15,814 | $73,08147 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $7,612 | $72,62580 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $90 | $18,62121 claims |
| Axsome Therapeutics, Inc.Auvelity | $23,734 | $13,32112 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $3,216162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Crestview Hills
- Molly LutzCrestview Hills$71K
- Sithandiwe MamutseCrestview Hills$13K
- Brent PlummerCrestview Hills$10K
- Amerika HullCrestview Hills$8K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.